Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Lu, Hongzhou; Zhang, George; Mao, John; Chen, Xiaochun; Zhan, Yangqing; Lin, Ling; Zhang, Tianxiang; Tang, Yanan; Lin, Feng; Zhu, Feiyue; Lin, Yuanlong; Zeng, Yiming; Zhang, Kaiyu; Yuan, Wenfang; Liang, Zhenyu; Sun, Ruilin; Huo, Liya; Hu, Peng; Lin, Yihua; Zhuang, Xibin; Wei, Zhaohui; Chen, Xia; Yan, Wenhao; Yan, Xiuping; Mu, Lisa; Lin, Zhuhua; Tu, Xinyu; Tan, Hongshan; Huang, Fuhu; Hu, Zhiqiang; Li, Hongming; Li, Guoping; Fu, Haijun; Yang, Zifeng; Chen, Xinwen; Wang, Fu-Sheng; Zhong, Nanshan

doi:10.1016/j.eclinm.2024.102582

eClinicalMedicine

2024

DOI: 10.1016/j.eclinm.2024.102582

|View full text |Cite

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Hongzhou Lu,

George Zhang,

John Mao

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Pan,

Zhou,

Yan

et al. 2025

Bioorganic Chemistry

View full text Add to dashboard Cite

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Pan,

Zhou,

Yan

et al. 2025

Bioorganic Chemistry

View full text Add to dashboard Cite

Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2

Guma,

Zhou,

Song

et al. 2025

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro)

Yang,

Luo,

Zhang

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Since 2019, the novel coronavirus (SARS-CoV-2) has caused significant morbidity and millions of deaths worldwide. The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2 and its variants, has further highlighted the urgent need for the development of effective therapeutic agents. Currently, the highly conserved and broadspectrum nature of main proteases (M pro ) renders them of great importance in the field of inhibitor study. In this study, we categorize inhibitors targeting M pro into three major groups: mimetic, nonmimetic, and natural inhibitors. We then present the research progress of these inhibitors in detail, including their mechanism of action, antiviral activity, pharmacokinetic properties, animal experiments, and clinical studies. This review aims to provide valuable insights and potential avenues for the development of more effective antiviral drugs against SARS-CoV-2.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Cited by 5 publications

References 22 publications

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro)

Contact Info

Product

Resources

About

Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial

Cited by 5 publications

References 22 publications

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities

Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)

Contact Info

Product

Resources

About

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M^pro)